Market Overview

UPDATE: Goldman Sachs Lowers PT on McKesson Corporation Following ABC/WAG Deal

Related MCK
Generic Drug Price Deflation Is Weighing On McKesson Shares
Goldman Drops McKesson To Neutral, Sees Limited Upside

In a report published Wednesday, Goldman Sachs analyst Robert P. Jones reiterated a Buy rating on McKesson Corporation (NYSE: MCK), but lowered the price target from $124.00 to $122.00.

In the report, Jones noted, “On our new estimates, ABC now trades at a 2x P/E multiple premium to MCK and CAH. While some may argue that ABC's valuation is justifiable given growth and support to numbers from the announced WAG deal, we find it difficult to overcome at current levels and maintain our Neutral rating. We still see the greatest risk/reward in MCK trading essentially at parity with CAH on our CY14, given (1) a more attractive growth profile through CY2014 after CAH's loss of WAG, (2) pending CVS contract renewals, which pose a risk for both, but greater for CAH at 31% of sales, versus MCK at 16%, and (3) a more attractive Specialty footprint - a differentiator in outer years.”

McKesson Corporation closed on Tuesday at $106.87.

Latest Ratings for MCK

Oct 2016UBSInitiates Coverage onNeutral
Sep 2016Goldman SachsDowngradesBuyNeutral
Aug 2016JP MorganMaintainsOverweight

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings


Related Articles (MCK)

View Comments and Join the Discussion!